Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COEP Coeptis Therapeutics	$13.21 -3.2%	$10.25	$2.31 ▼ $14.70	$63.67M	-0.59	82,032 shs	37,720 shs
KALA KALA BIO	$9.31 +6.0%	$6.41	$2.92 ▼ $11.20	$65.36M	-1.81	88,987 shs	120,058 shs
MNOV MediciNova	$1.36 +3.0%	$1.30	$1.13 ▼ $2.55	$64.37M	0.35	21,066 shs	10,474 shs
MRKR Marker Therapeutics	$1.00 -20.6%	$1.45	$0.95 ▼ $5.95	$12.94M	1.45	810,833 shs	45.13 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COEP Coeptis Therapeutics	+1.41%	-6.83%	+17.37%	+48.53%	+232.93%
KALA KALA BIO	-4.67%	+2.33%	+8.53%	+116.26%	+46.09%
MNOV MediciNova	+0.58%	+0.76%	-9.59%	-7.69%	+8.20%
MRKR Marker Therapeutics	-2.33%	+4.13%	-19.23%	+9.57%	-65.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COEP Coeptis Therapeutics	0.699 of 5 stars	0.0	3.0	0.0	2.7	1.7	0.0
KALA KALA BIO	3.4668 of 5 stars	3.5	2.0	4.4	0.0	0.8	0.6
MNOV MediciNova	2.2604 of 5 stars	3.8	3.0	0.0	2.2	0.8	0.0
MRKR Marker Therapeutics	3.368 of 5 stars	3.8	2.0	3.9	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COEP Coeptis Therapeutics	0.00	N/A	N/A	N/A
KALA KALA BIO	3.00	Buy	$13.00	39.63% Upside
MNOV MediciNova	3.50	Strong Buy	$7.00	414.71% Upside
MRKR Marker Therapeutics	3.50	Strong Buy	$13.17	1,216.67% Upside

Current Analyst Ratings Breakdown

Latest MRKR, COEP, KALA, and MNOV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/24/2025	MNOV MediciNova	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
7/11/2025	KALA KALA BIO	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/16/2025	MNOV MediciNova	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy ➝ Strong-Buy	$6.00 ➝ $5.00
6/2/2025	KALA KALA BIO	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$15.00

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	$1.61 per share	N/A
KALA KALA BIO	$3.89M	16.80	N/A	N/A	$2.02 per share	4.61
MNOV MediciNova	$1M	N/A	N/A	N/A	$1.07 per share	N/A
MRKR Marker Therapeutics	$6.59M	1.96	N/A	N/A	$1.73 per share	0.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COEP Coeptis Therapeutics	-$10.88M	-$5.80	N/A	∞	N/A	N/A	-201.73%	-108.46%	N/A
KALA KALA BIO	-$38.51M	-$6.79	N/A	N/A	N/A	N/A	-686.43%	-76.81%	11/11/2025 (Estimated)
MNOV MediciNova	-$11.04M	-$0.25	N/A	N/A	N/A	N/A	-23.12%	-21.85%	11/12/2025 (Estimated)
MRKR Marker Therapeutics	-$10.73M	-$1.37	N/A	N/A	N/A	-271.12%	-114.59%	-90.31%	11/13/2025 (Estimated)

Latest MRKR, COEP, KALA, and MNOV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	COEP Coeptis Therapeutics	N/A	-$1.17	N/A	-$1.17	N/A	$0.20 million
8/14/2025	Q2 2025	MNOV MediciNova	-$0.07	-$0.07	N/A	-$0.07	N/A	$0.14 million
8/14/2025	Q2 2025	MRKR Marker Therapeutics	-$0.55	-$0.29	+$0.26	-$0.29	$0.72 million	$0.86 million
8/8/2025	Q2 2025	KALA KALA BIO	-$1.82	-$1.71	+$0.11	-$1.71	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A
MNOV MediciNova	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COEP Coeptis Therapeutics	0.02	0.83	0.83
KALA KALA BIO	3.19	2.10	2.10
MNOV MediciNova	N/A	13.26	13.26
MRKR Marker Therapeutics	N/A	3.45	3.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COEP Coeptis Therapeutics	13.88%
KALA KALA BIO	24.61%
MNOV MediciNova	9.90%
MRKR Marker Therapeutics	22.39%

Insider Ownership

Company	Insider Ownership
COEP Coeptis Therapeutics	24.25%
KALA KALA BIO	8.32%
MNOV MediciNova	13.60%
MRKR Marker Therapeutics	7.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COEP Coeptis Therapeutics	2	4.82 million	3.65 million	Not Optionable
KALA KALA BIO	30	7.02 million	6.44 million	Not Optionable
MNOV MediciNova	10	N/A	N/A	Optionable
MRKR Marker Therapeutics	60	12.94 million	11.93 million	Not Optionable

MRKR, COEP, KALA, and MNOV Headlines

Recent News About These Companies

Marker Therapeutics Stock Drops After Report About Lymphoma Treatment

August 26 at 12:34 PM | benzinga.com

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

August 26 at 7:00 AM | globenewswire.com

Marker Therapeutics (NASDAQ:MRKR) Raised to "Sell" at Wall Street Zen

August 19, 2025 | americanbankingnews.com

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

July 30, 2025 | globenewswire.com

Marker Therapeutics Insider Trading Activity | NASDAQ:MRKR | Benzinga

July 18, 2025 | benzinga.com

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

July 11, 2025 | finance.yahoo.com

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

June 17, 2025 | globenewswire.com

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

May 20, 2025 | globenewswire.com

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

May 19, 2025 | globenewswire.com

Arkansas Historic Preservation Program hosts National Historic Marker Weekend

April 17, 2025 | stuttgartdailyleader.comS

Marker Therapeutics (MRKR) Receives a Buy from Canaccord Genuity

April 1, 2025 | markets.businessinsider.com

Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference

April 1, 2025 | markets.businessinsider.com

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

April 1, 2025 | globenewswire.com

Marker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last year

March 31, 2025 | markets.businessinsider.com

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

March 31, 2025 | globenewswire.com

Marker Therapeutics stockholder vote clears warrant issuance

March 28, 2025 | investing.com

Marker Therapeutics initiated with a Buy at Canaccord

March 5, 2025 | markets.businessinsider.com

Canaccord Genuity Initiates Coverage of Marker Therapeutics (MRKR) with Buy Recommendation

March 5, 2025 | msn.com

Marker Therapeutics, Inc. CEO Juan Vera to Present at H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

February 25, 2025 | quiverquant.comQ

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

February 25, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR, COEP, KALA, and MNOV Company Descriptions

Coeptis Therapeutics NASDAQ:COEP

$13.21 -0.44 (-3.22%)

Closing price 03:59 PM Eastern

Extended Trading

$13.17 -0.04 (-0.30%)

As of 06:09 PM Eastern

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

KALA BIO NASDAQ:KALA

$9.31 +0.53 (+6.04%)

Closing price 04:00 PM Eastern

Extended Trading

$9.21 -0.10 (-1.03%)

As of 06:57 PM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

MediciNova NASDAQ:MNOV

$1.36 +0.04 (+3.03%)

Closing price 03:46 PM Eastern

Extended Trading

$1.62 +0.27 (+19.49%)

As of 07:32 PM Eastern

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Marker Therapeutics NASDAQ:MRKR

$1.00 -0.26 (-20.63%)

Closing price 04:00 PM Eastern

Extended Trading

$0.98 -0.02 (-2.10%)

As of 07:31 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time